Oxyrane brings on board senior team
pharmafile | January 30, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Oxyrane, biotech
UK biotech firm Oxyrane has expanded to the US and made a number of senior appointments.
The privately-owned Manchester-based company’s first US recruitment step was to appoint Dr Charles ‘Charlie’ Richard as chief medical officer. Richard (pictured) is an expert in LSDs with over 10 years’ drug development experience in the rare and orphan disease space. He joins from Shire Human Genetic Therapies where, since 2006, he was principal medical director and head of Translational Medicine in Clinical R&D.
Also appointed as vice president of Regulatory Affairs is James ‘Jim’ Weston, who has over 30 years’ experience in the development of biological and pharmaceutical products, and has directed strategy for development programs in the US, Canada, Europe, Australia and Japan resulting in the approval of 11 drugs/biologics worldwide. Weston joins Oxyrane from his previous role as US head of Regulatory Affairs for rare and orphan diseases at Shire Human Genetic Therapies.
Finally Susan Flint joins as executive director and head Clinical Operations. Flint is an accomplished senior executive with over 30 years’ experience in multinational drug development including: executive management, regulatory affairs, clinical operations and has led several international multi-million dollar clinical trials in a variety of therapeutic areas. Flint joins Oxyrane from her previous role as program director at Navidea Biopharmaceuticals.
Michael Campbell, chief executive of Oxyrane said: “We now have in place a top team of commercial, clinical and regulatory experts with a proven track record of success in the orphan space. I look forward to working with them as we progress towards developing our clinical programme and beyond.”
Related Content
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
